Quantcast
Last updated on April 25, 2014 at 1:22 EDT

Latest Chronic Pruritus Stories

2014-03-21 12:22:51

CANTERBURY, England, March 21, 2014 /PRNewswire/ -- - Phase 2b data demonstrates a 60% reduction in pruritus in psoriatic patients treated with CT327 - Data analysis also published in the Journal of the American Academy of Dermatology - Phase 2b CT327 topline data in patients with Atopic Dermatitis and Pruritus due in mid-2014 Creabilis Ltd, the dermatology company with the most advanced targeted topical...

2013-09-18 04:22:57

CANTERBURY, England, September 18, 2013 /PRNewswire/ -- Creabilis, a late clinical stage European dermatology company with a focus on pruritus (itch), today announces it has treated the first patients in its Phase 2b study of its lead product, CT327, in patients with atopic dermatitis (AD). The Phase 2b trial is a multi-centre, randomised, double-blind, placebo-controlled study in adult and adolescent patients (older than 12 years) with mild to moderate atopic...

2013-07-29 04:21:23

CANTERBURY, England, July 29, 2013 /PRNewswire/ -- Creabilis SA, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces that it has appointed Professor Gil Yosipovitch and Professor Praveen Anand to its Scientific Advisory Board. Gil Yosipovitch is the newly announced Chair of the Department of Dermatology and Director of the Temple Itch Center at Temple University School of Medicine, and is one of the world's renowned experts...

2013-05-10 04:21:38

LUXEMBOURG, May 10, 2013 /PRNewswire/ -- Clinically and Statistically Significant Reduction of Chronic Pruritus (Itch) Seen in Psoriasis Patients Creabilis, a late stage European dermatology company with a focus on chronic pruritus (itch), today announces headline results of its Phase 2b trial with its lead product, CT327, in psoriasis patients. CT327 is a novel, topical, TrkA kinase inhibitor developed using Creabilis' LSE (Low Systemic Exposure) technology that creates 'topical-by-design'...